Marking a significant quarter-century, Grifols’ Derio facility in Bizkaia commemorates 25 years of dedicated advancements in transfusion medicine and diagnostic innovation, reinforcing the company’s position as a leader in global healthcare solutions.
A Legacy of Pioneering Diagnostic Innovations
Established in 2000 under the name Progenika and acquired by Grifols in 2013, the Derio center has been instrumental in developing groundbreaking diagnostic tools. Early achievements include the launch of the first CE-marked genetic test for familial hypercholesterolemia in 2004 and the introduction of blood genotyping products in 2008, setting new standards in the field.
Responding to Global Health Challenges
The Derio facility demonstrated remarkable agility during the COVID-19 pandemic by swiftly developing a highly sensitive molecular test for SARS-CoV-2. This innovation played a critical role in testing efforts across Spain, highlighting the center’s capacity to respond effectively to urgent public health needs.
Moreover, the development of the AlphaID™ test addresses genetic risks for alpha1-antitrypsin deficiency, a leading cause of COPD, showcasing the center’s commitment to tackling chronic respiratory conditions through advanced diagnostics.
– Derio center’s consistent innovation drives Grifols’ leadership in diagnostics.
– Rapid COVID-19 test development underscores agility and responsiveness.
– Automation platforms aim to enhance global blood bank operations.
– Revenue growth reflects strong market demand and strategic investments.
Looking ahead, Grifols plans to expand its diagnostic portfolio by launching new generations of molecular, immunoassay, and blood typing assays. These advancements are set to provide fully automated solutions for laboratories worldwide, further cementing the company’s role in enhancing transfusion safety and disease diagnosis.
With over 95 dedicated professionals at the Derio site, Grifols continues to invest in research and development to deliver effective diagnostic solutions. This sustained investment not only strengthens the company’s market position but also contributes to improved patient outcomes and the overall quality of healthcare services.
Grifols’ unwavering dedication to innovation and excellence at the Derio center exemplifies how sustained R&D efforts can lead to significant advancements in medical diagnostics, ultimately benefiting patients and healthcare providers globally.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
